SL Science Presents Benefits Of Gamma Delta T Cells In Eliminating Glioblastoma In Preclinical Studies At The 2026 World Congress Of Basic And Clinical Pharmacology

SL Science Highlighted The Filing Of A New Drug Master File With The U.S. FDA Covering Exosomes Derived From Gamma Delta T Cells

SL Science Holding Limited ("SL Science" or the "Company") (NASDAQ:SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of

SL Science Highlights New FDA Drug Master File For GDT Cell-Derived Exosomes

SL Science Announces Publication Of Peer-Reviewed Article In 'Biomedicines' Outlining A Rigorous Development Framework For γδ T Cell Therapy In Glioblastoma

Glioblastoma a common and aggressive primary brain cancer in adults. Beyond reviewing existing literature, the paper outlines the specific clinical trial designs, biological measurements, and testing conditions required